Latest Period
Q4 2025
Security Snapshot
Travere Therapeutics, Inc. - Common Stock (TVTX) Institutional Ownership
CUSIP: 89422G107
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
274
Shares (Excl. Options)
102,161,535
Price
$38.21
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- TVTX on Nasdaq
- Shares outstanding
- 92,326,601
- Price per share
- $30.70
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 102,161,535
- Total reported value
- $3,903,877,547
- % of total 13F portfolios
- 0%
- Share change
- -2,667,207
- Value change
- +$8,107,644
- Number of holders
- 274
- Price from insider filings
- $30.70
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TVTX - Travere Therapeutics, Inc. - Common Stock is tracked under CUSIP 89422G107.
- 274 institutions reported positions in Q4 2025.
- 9 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 274 to 61 between Q4 2025 and Q1 2026.
- Reported value moved from $3,903,877,547 to $281,680,702.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 274 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 89422G107?
CUSIP 89422G107 identifies TVTX - Travere Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 89422G107:
Significant Owners of Travere Therapeutics, Inc. - Common Stock (TVTX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 12% | -6.9% | $253,331,874 | -$17,690,876 | 10,599,660 | -6.5% | JANUS HENDERSON GROUP PLC | 30 Sep 2025 |
| FMR LLC | 12% | $403,768,185 | 10,567,303 | FMR LLC | 31 Dec 2025 | |||
| BlackRock, Inc. | 7.5% | -21% | $122,617,344 | -$24,357,949 | 6,689,435 | -17% | BlackRock, Inc. | 31 Mar 2025 |
| STATE STREET CORP | 5.3% | $138,466,547 | 4,756,666 | STATE STREET CORPORATION | 31 Dec 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | $139,619,887 | 4,699,424 | Vanguard Capital Management | 31 Mar 2026 | |||
| PERCEPTIVE ADVISORS LLC | 4.8% | -12% | $124,537,820 | -$17,973,533 | 4,278,180 | -13% | Perceptive Advisors LLC | 31 Dec 2025 |
| ARMISTICE CAPITAL, LLC | 4.2% | -41% | $104,899,642 | -$82,498,238 | 3,763,891 | -44% | Armistice Capital, LLC | 31 Dec 2025 |
| Rock Springs Capital Management LP | 3.3% | -40% | $53,545,523 | -$37,621,463 | 2,921,196 | -41% | Rock Springs Capital Management LP | 31 Mar 2025 |
| Woodline Partners LP | 2.4% | $38,750,646 | 2,114,056 | Woodline Partners LP | 31 Dec 2024 |
As of 31 Dec 2025, 274 institutional investors reported holding 102,161,535 shares of Travere Therapeutics, Inc. - Common Stock (TVTX). This represents 111% of the company’s total 92,326,601 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Travere Therapeutics, Inc. - Common Stock (TVTX) together control 83% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 11% | 10,511,166 | -0.83% | 0.18% | $401,715,922 |
| FMR LLC | 10% | 9,617,863 | +232% | 0.02% | $367,498,538 |
| BlackRock, Inc. | 8.5% | 7,869,352 | -2.9% | 0.01% | $300,687,941 |
| VANGUARD GROUP INC | 6.8% | 6,309,229 | -4.6% | 0% | $241,075,642 |
| STATE STREET CORP | 5.2% | 4,756,666 | +48% | 0.01% | $181,752,208 |
| PERCEPTIVE ADVISORS LLC | 4.6% | 4,278,180 | +13% | 3% | $163,469,258 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 4.1% | 3,773,564 | 0% | 0.22% | $144,188,000 |
| ARMISTICE CAPITAL, LLC | 4.1% | 3,763,891 | -44% | 3.5% | $143,818,275 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.2% | 2,927,000 | -18% | 0.17% | $111,840,670 |
| RENAISSANCE TECHNOLOGIES LLC | 2.4% | 2,246,779 | +28% | 0.13% | $85,849,426 |
| Rock Springs Capital Management LP | 2.4% | 2,210,322 | +2.1% | 4.3% | $84,456,404 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 2,143,495 | +0.26% | 0.01% | $81,915,213 |
| GOLDMAN SACHS GROUP INC | 2% | 1,868,212 | +47% | 0.01% | $71,384,380 |
| BANK OF AMERICA CORP /DE/ | 2% | 1,850,355 | +32% | 0.01% | $70,702,066 |
| Stephens Investment Management Group LLC | 1.9% | 1,721,623 | +7.6% | 0.86% | $65,783,215 |
| EMERALD ADVISERS, LLC | 1.7% | 1,594,184 | -26% | 1.9% | $60,913,771 |
| MORGAN STANLEY | 1.5% | 1,415,897 | +27% | 0% | $54,101,442 |
| Eversept Partners, LP | 1.3% | 1,174,968 | -17% | 2.5% | $44,895,527 |
| TWO SIGMA INVESTMENTS, LP | 1.3% | 1,156,807 | +25% | 0.07% | $44,201,595 |
| D. E. Shaw & Co., Inc. | 1.2% | 1,094,556 | +65% | 0.03% | $41,822,985 |
| Nuveen, LLC | 1.1% | 993,613 | -7.9% | 0.01% | $37,965,953 |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1% | 948,459 | -21% | 1.8% | $36,240,618 |
| Driehaus Capital Management LLC | 0.98% | 901,404 | +27% | 0.23% | $34,442,647 |
| DEUTSCHE BANK AG\ | 0.95% | 881,680 | -45% | 0.01% | $33,688,992 |
| Fiera Capital Corp | 0.95% | 874,053 | 0.11% | $33,397,565 |
Institutional Holders of Travere Therapeutics, Inc. - Common Stock (TVTX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 9,516,759 | $281,680,702 | +$18,608,924 | $29.71 | 61 |
| 2025 Q4 | 102,161,535 | $3,903,877,547 | +$8,107,644 | $38.21 | 274 |
| 2025 Q3 | 100,727,863 | $2,407,390,168 | +$19,761,610 | $23.90 | 235 |
| 2025 Q2 | 100,531,635 | $1,487,836,300 | +$12,972,115 | $14.80 | 207 |
| 2025 Q1 | 98,007,579 | $1,771,747,554 | +$87,075,624 | $17.92 | 214 |
| 2024 Q4 | 95,064,656 | $1,655,970,325 | +$204,069,962 | $17.42 | 194 |
| 2024 Q3 | 82,734,245 | $1,157,476,987 | -$64,293,173 | $13.99 | 175 |
| 2024 Q2 | 87,955,117 | $723,000,948 | +$2,540,410 | $8.22 | 168 |
| 2024 Q1 | 87,706,388 | $676,170,447 | +$11,374,907 | $7.71 | 172 |
| 2023 Q4 | 85,573,515 | $769,316,791 | +$27,493,568 | $8.99 | 162 |
| 2023 Q3 | 82,430,217 | $736,935,857 | -$48,196,261 | $8.94 | 166 |
| 2023 Q2 | 82,714,633 | $1,270,488,775 | -$85,984,898 | $15.36 | 165 |
| 2023 Q1 | 84,151,882 | $1,892,538,812 | +$263,849,900 | $22.49 | 171 |
| 2022 Q4 | 72,978,794 | $1,535,405,782 | +$36,464,951 | $21.03 | 153 |
| 2022 Q3 | 69,779,173 | $1,719,469,986 | -$2,015,044 | $24.64 | 168 |
| 2022 Q2 | 69,489,567 | $1,683,983,339 | +$17,370,839 | $24.23 | 166 |
| 2022 Q1 | 69,479,485 | $1,789,961,946 | +$97,223,694 | $25.77 | 166 |
| 2021 Q4 | 65,477,167 | $2,032,139,426 | +$61,452,684 | $31.04 | 165 |
| 2021 Q3 | 60,858,590 | $1,476,104,164 | +$4,235,576 | $24.25 | 145 |
| 2021 Q2 | 60,583,594 | $883,983,031 | -$73,514,650 | $14.59 | 131 |
| 2021 Q1 | 62,621,768 | $1,563,390,183 | +$254,685,025 | $24.97 | 147 |
| 2020 Q4 | 52,293,956 | $1,423,328,983 | +$1,416,953,984 | $27.26 | 135 |